群发资讯网

返回主页
biopharmaceuticals
生技药品
常用释义
英式发音
美式发音
基本释义
  • n. 生技药品
例句
  • 1·The history, present facts and market of biopharmaceuticals were reviewed in this article.
    本文综述了生物制药的历史、现状和市场。
  • 2·Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries.
    生物制药是在医药和生物技术产业的主要增长动力之一。
  • 3·The group ultimately aims to develop its own biopharmaceuticals after gaining experience in making them, he said.
    他说,该九团的最终目标是通过生产获得经验以期能够开发出自己的生物药品。
  • 4·However, among the about 150 biopharmaceuticals on the market by 2004, only insulin has been marketed in crystalline form.
    然而,截至2004年的150多种生物药中,以晶体为其主要的生产和销售形态的药物只有胰岛素。
  • 5·Prodrug is an effective way to improve the oral absorption of the drugs which belong to Biopharmaceuticals Classification System(BCS) class III and IV.
    前药研究是提高生物药剂学分类系统中第III和IV类药物口服吸收的有效途径之一。
  • 6·Screening novel products with bioactivities, such as antibodies, receptors and vaccines has become a convenient way to develop novel biopharmaceuticals.
    用表面呈现技术构建文库并从中筛选新的生物活性物质,如抗体、 受体或疫苗,已成为研究生物新药的捷径之一。
  • 7·Biopharmaceuticals are pharmaceutical products consisting of (glyco) proteins, and they have a number of characteristics that set them aside from low molecular weight drugs.
    生物药剂是含有(糖)蛋白的药物制剂,它们具有许多与小分子量药物不同的特性。
  • 8·Alder Biopharmaceuticals, Inc. uniquely identifies, develops, and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas.
    桤木生物药业公司唯一识别,开发和制造新型抗体治疗,以减轻人类苦难的自身免疫性和炎症性疾病领域。
  • 9·The complete sequencing of CHO-K1 genome is a major step forward in the application of genomics in the production of biopharmaceuticals, " stated Dr. Jun Wang, Executive Director of BGI."
    深圳华大基因研究院执行总裁王俊博士说:CHO细胞系基因组测序的完成是实现基因组学应用于生物医药生产的非常重要的一步。
  • 10·The Seoul-based group may exceed its target to generate 1.8 trillion won a year by 2020 from biopharmaceuticals because of the demand for those medicines, Executive Vice President Kim Tae Han said.
    三星集团总部位于韩国首尔,其执行副总裁金泰韩(Kim Tae Han)称,基于生物药品的需求,三星集团到2020年的年销售额将达到1.8万亿韩元,超过其既定目标。